PDGFRB

Across TCGA pan-cancer cohorts, PDGFRB mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PDGFRB data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PDGFRB mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PDGFRB expression acts as an unfavorable survival marker.

PDAC, LSCC, and CCRCC are the cancer types where PDGFRB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.205	0.379	.008	10	view →
LSCC	OS	Median	All	0.800	1.000	.044	2	view →
CCRCC	OS	Median	II,III,IV	0.554	1.000	.025	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PDGFRB–PDAC (DFS)

Open the PDAC breakdown →